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ABSTRACT
Introduction: Stomatitis is a common and
potentially dose-limiting adverse event of the
mammalian target of rapamycin (mTOR)
inhibitor therapy. To minimize dose
reductions or treatment delays that may affect
therapeutic outcomes, management includes
patient education, pain management
strategies, and drug treatment. The aim of this
study was to evaluate the effectiveness of a
topically-applied galenical preparation to
minimize the impact of everolimus-associated
oral mucositis in patients with advanced cancer.
Methods: Patients receiving everolimus plus
exemestane for advanced breast cancer or
everolimus alone for advanced renal cancer were
eligible for inclusion. All patients were advised on
procedures to maintain good oral hygiene and
directed to use a dexamethasone-containing
galenical preparation at the first signs of
mucositis. Questionnaires were administered at
baseline, and after cycles one, two, and three to
evaluate the presence, duration, and intensity of
oral mucositis.
Results: Of the 19 patients included in the
study (mean age 66 years; 16% male), mucositis
developed in 10.5%, 47.4%, and 52.6% of
patients after the first, second, and third cycles
of everolimus, respectively. The median time to
development of mucositis was 18.0 days, and
the median time to mucositis resolution was
30.0 days. After the first, second, and third
cycles of therapy, 5.3%, 10.5%, and 10.5% of
patients required interruption of everolimus
therapy; however, no dosage reductions for
mucositis were necessary.
Conclusions: Patient education and the
provision of an effective galenical preparation
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can minimize the effect of mTOR
inhibitor-related mucositis.
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INTRODUCTION
The orally administered mammalian target of
rapamycin (mTOR) inhibitor, everolimus, has
clinical activity against a range of malignancies
and is currently indicated for the treatment of
advanced solid tumors, including renal cell
carcinoma and hormone receptor-positive,
human epidermal growth factor receptor
2-negative breast cancer recurring or progressing
after nonsteroidal aromatase inhibitor therapy
[1–3]. Everolimus is generally well tolerated,
with an adverse event profile consisting of
manageable side effects such as rash, diarrhea,
fatigue, infections, stomatitis, noninfectious
pneumonitis, and metabolic abnormalities,
mostly mild-to-moderate in severity [1, 2, 4, 5].
As everolimus has the potential for prolonged
use, it is important that physicians are able to
recognize, monitor, and effectively manage its
adverse events to ensure patient adherence,
optimize health-related quality of life, and
minimize toxicity. Stomatitis, or more
specifically, oral mucositis, is one of the
most common and potentially dose-limiting
adverse events associated with mTOR inhibitor
use, including everolimus [6, 7], with an
incidence as high as 60% reported in trials
[1, 2, 8, 9]. mTOR inhibitor-related mucositis is
distinct from typical chemotherapy-related
stomatitis, often presenting as distinct, painful,
ovoid, superficial, well-demarcated ulcers
with a grayish-white pseudomembrane and
accompanied by erythema, edema, a burning
sensation, and occasional bleeding [8, 9]. The
stomatitis normally develops on mobile, less
keratinized mucosa (inner lip, ventral and lateral
surfaces of the tongue, and the soft palate) and
not on keratinized mucosa (hard palate, gums,
and back of the tongue). Mucositis often
develops in the first 2 weeks after starting
therapy, and symptoms may resolve or level off
at approximately 6 weeks [10, 11].
Part of the management strategy of
mTOR-related oral mucositis includes patient
education in oral hygiene, diet modifications,
and pain management strategies. Interventions
to prevent or treat mTOR inhibitor-induced
mucositis may include a range of topical
preparations, such as corticosteroids and
anti-inflammatories, along with supportive
treatments such as local anesthetics and
topical antimicrobial agents [6, 7, 9, 10].
Nonsteroidal anti-inflammatory drugs (NSAIDs)
or acetaminophen may be useful for pain
relief in persistent mucositis, and systemic or
intra-lesional treatment with high-dose
corticosteroids may be necessary in severe or
refractory cases. The use of weak or strong
opioids is seldom necessary [6, 7, 9, 10, 12].
This retrospective study aimed to evaluate the
impact of a dexamethasone-containing topical
galenical for the management of oral mucositis
related to the use of an mTOR inhibitor in
patients with metastatic breast or renal cancer.
METHODS
Patients and Treatment Plan
Eligible patients were receiving everolimus
treatment for metastatic breast cancer or
metastatic renal cancer between April 3, 2012
and March 17, 2015 at the Unit of Medical
Oncology of the Hospital ‘‘Annunziata’’ of
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Cosenza, Italy. At this hospital, patients
receiving everolimus attend a day service clinic
dedicated to oral therapies, which allows
constant monitoring of appropriate laboratory
and clinical parameters and the early detection
of toxicities. All patients receiving everolimus
were advised on procedures to maintain good
oral hygiene, such as using mouthwashes
devoid of alcohol (e.g., sodium bicarbonate),
flossing after every meal, the careful use of
toothpaste and a soft bristle toothbrush,
avoidance of products containing hydrogen
peroxide, iodine, and derivatives of the
thymus, and the avoidance of spicy, fatty or
very salty foods. Patients were also educated on
how to prevent possible outbreaks of infection
(such as periodontal disease and granulomas).
To be included in the analysis, patients with
breast cancer received everolimus if they (1) had
metastatic disease; (2) were hormone receptor
(estrogen receptor, progesterone receptor)
positive; (3) had received two previous lines of
chemotherapy; (3) had disease progression
during or after previous treatment with a
non-steroidal aromatase inhibitor; (4) had no
symptomatic visceral metastases; (5) were
menopausal; (6) had not received everolimus
previously; and (7) had normal liver function.
Patients with renal cancer were required to be
already on treatment with everolimus for the
indication of renal cancer.
All breast cancer patients had undergone one
or more cycles of chemotherapy or hormonal
therapy (not including exemestane). Patients
with renal cell carcinoma were given treatment
with everolimus after they had presented with
disease progression during or after treatment
with vascular endothelial growth factor
(VEGF)-targeted therapy. Everolimus was
prescribed at the standard dose of 10 mg orally
once daily, which could be reduced in response
to toxicity. Everolimus treatment was
suspended only in the case of serious toxicity
(Cgrade 2). Patients with metastatic breast
cancer who were receiving concomitant
exemestane received everolimus 10 mg orally
once daily plus exemestane 25 mg orally once
daily.
Patients underwent a battery of complete
blood chemistry tests with particular attention
to complete blood count and cholesterol,
triglycerides, and blood glucose levels. Patient
evaluations to monitor cancer response/disease
progression included clinical assessment,
computed tomography, and ultrasound
mammography.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
Galenical Formulation
A topical galenical for the management of
mucositis was prepared independently by
the pharmacist at our hospital pharmacy
according to the procedure and standards of
the Italian edition of the European Pharmacopoeia
of the Council of Europe, the Italian Society of
Pharmacists, and Good Manufacturing
Practice. The galenical formulation consisted
of dexamethasone 0.024 g, sweet almond
oil 1 g, rose honey 15 g, glycerol 15 g,
and hydroxyethylcellulose 1.2 g. The
resulting odorless, brown, semi-solid, non-
sterilized, microbial-controlled preparation was
manufactured for application to the oralmucosa.
Thepreparationwas stored inacontainermadeof
bakelite and kept refrigerated at 2–8 C.
Patients were instructed to use the galenical
preparation at the first appearance of oral
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mucositis; three times a day for the first 7 days,
then twice daily for the next 7 days, then once a
day for the following 2 weeks. Application was
by a Garrison disposable (bandages, tongue
depressors).
Study Endpoints
The primary objectives of the analysis were to
evaluate the presence, duration and intensity of
oral mucositis, both reported by the patient and
evaluated by the clinician, during the first three
cycles of therapy with everolimus, by assessing
duration and severity of symptoms, and to
evaluate the usefulness of the topical galenical
for the management of oral mucositis in these
patients undergoing treatment with everolimus.
Evaluation and Treatment of Mucositis
Data were collected using four specific
questionnaire forms at predetermined time
points during the first three cycles of
everolimus treatment (see Supplementary
Material for the four questionnaires used in
the study). The written questionnaires were
completed on cycle 1 day 1 (baseline), after
the first cycle of everolimus treatment (cycle
1 day 8), and after the second and third (last
observation) cycles. The questionnaires
recorded patient demographics, characteristics
of the patients at baseline (primary tumor,
staging, metastatic site, performance status,
line of treatment, presence/absence of
mucositis, systemic analgesic therapy for
background disease or mucositis-related pain),
time to appearance and objective and subjective
assessments of mucositis severity, time to
resolution and/or reduction in grade of
mucositis, any everolimus dose interruptions
required, and the percentage of patients
discontinuing everolimus due to mucositis.
Mucositis pain was assessed using the mTOR
inhibitor-associated stomatitis (mIAS) scale,
specifically developed to assess mTOR
inhibitor-related stomatitis [13]. The scale
comprises subjective (patient-rated) and
objective (clinician-rated) classification criteria
and includes duration of mTOR inhibitor-
related ulceration and severity of associated
pain, and persistence of lesions and pain.
The subjective grading criteria range from
grade 0 (no pain) to grade 3 (pain score of C6
on a 10-point scale). The objective grading
criteria range from grade 0 (no visible lesion)
to grade 3 (lesion/s persisting for C7 days).
MTOR inhibitor dose-modification should be
considered only when both subjective and
objective assessments are grade 3, indicating
persistent lesions with significant pain despite
the use of analgesics or other palliative care [13].
Statistical Analysis
Statistical aggregate analysis of the collected
data was used to describe the time course of
mucositis development, severity and resolution,
treatment interruptions due to mucositis, and
the usefulness of the topical galenical for the
management of mucositis pain and symptoms.
RESULTS
Patient Characteristics
Data from 19 patients (mean age 66.1 years;
84.2% female) were analysed. The majority of
baseline characteristics and previous treatments
were balanced between the study population
(Table 1). However, the primary tumor site was
the breast in only the female patients included
in the analysis (all were receiving everolimus
plus exemestane) while the primary tumor site
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Table 1 Baseline characteristics and treatments of the population by tumor type
Characteristic Breast cancer (N5 16) Renal cancer (N5 3) Total (N5 19)
Mean ± SD age, years 64.2 (11.68) 75.7 (2.08) 66.1 (11.49)
Gender, n (%)
Female 16 (100.0) 0 16 (84.2)
Male 0 3 (100.0) 3 (15.8)
Tumor size, n (%)a
T2 9 (56.3) 0 9 (47.4)
T3 3 (18.8) 3 (100.0) 6 (31.6)
T4 4 (25.0) 0 4 (21.1)
Nodal status, n (%)a
N0 2 (12.5) 2 (66.7) 4 (21.1)
N1 10 (62.5) 1 (33.3) 11 (57.9)
N2 3 (18.8) 0 3 (16.8)
N3 1 (6.3) 0 1 (5.3)
Metastasis site, n (%)
Visceral 5 (31.3) 1 (33.3) 6 (31.6)
Bone 8 (50.0) 0 8 (42.1)
Visceral ? bone 3 (18.8) 2 (66.7) 5 (26.3)
ECOG performance status, n (%)
0 1 (6.3) – 1 (5.3)
1 11 (68.8) 1 (33.3) 12 (63.2)
2 4 (25.0) 2 (66.7) 6 (31.6)
Mucositis at baseline, n (%) 0 0 0
Mucositis prevention followed, n (%) 16 (100.0) 3 (100.0) 19 (100.0)
Cancer therapy
Everolimus 0 3 (100.0) 3 (15.8)
Everolimus ? exemestane 16 (100.0) 0 16 (84.2)
Therapy line
I 2 (12.5) 0 2 (10.5)
II 6 (37.5) 3 (100.0) 9 (47.4)
III 6 (37.5) 0 6 (31.6)
IV 1 (6.3) 0 1 (5.3)
V 0 0 0
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was the kidney in the three male patients
(everolimus only). Metastatic site was bone
(42.1%), viscera (31.6%) or both (26.3%).
Everolimus was second- or third-line treatment
in 79.0% of patients. The majority of men had
an Eastern Cooperative Oncology Group
(ECOG) performance status of 2, while most
women had an ECOG performance status of 1.
At baseline, 25.0% of women were receiving
pain therapy, primarily with NSAIDs. No men
were receiving analgesics at baseline.
Time Course of Mucositis Development
and Resolution
On day 8, after the first cycle of everolimus,
two patients (10.5%) had mucositis, which
was moderately painful in one patient and
severe in the other (Table 2), and with a
mucositis degree of grade 2 in one patient
and grade 3 in the other. After the
second and third cycles, nine (47.4%) and
10 (52.6%) patients, respectively, had
Table 1 continued
Characteristic Breast cancer (N5 16) Renal cancer (N5 3) Total (N5 19)
VI 1 (6.3) 0 1 (5.3)
Received treatment for pain, n (%) 4 (25.0) 0 4 (21.1)
Pain treatment received, n (%)
NSAIDs 4 (25.0) 0 4 (21.1)
Opioids 1 (6.3) 0 1 (5.3)
ECOG Eastern Cooperative Oncology Group, NSAIDs nonsteroidal anti-inﬂammatory drugs, SD standard deviation
a Assessed using TNM staging
Table 2 Patients with mTOR inhibitor-associated mucositis, by treatment cycle
n (%) First cycle Second cycle Third cycle
Patients with mucositis 2 (10.5) 9 (47.4) 10 (52.6)
Pain intensity (mIAS Scalea; patient-assessed)
Grade 0 (no pain) 17 (89.5) 10 (52.6) 9 (47.4)
Grade 1 (mild pain) 0 2 (10.5) 0
Grade 2 (moderate pain) 1 (5.3) 4 (21.1) 6 (31.6)
Grade 3 (severe pain) 1 (5.3) 3 (15.8) 4 (21.1)
Mucositis degree (mIAS Scalea; clinician-assessed)
Grade 0 (no visible stomatitis) 17 (89.5) 10 (52.6) 9 (47.4)
Grade 1 (oral and/or pharyngeal heritema without ulcerations) 0 2 (10.5) 0
Grade 2 (visible oral and/or pharyngeal ulcerations for a duration of\7 days) 1 (5.3) 4 (21.1) 6 (31.6)
Grade 3 (visible oral and/or pharyngeal ulcerations C1 persisting for C7 days) 1 (5.3) 3 (15.8) 4 (21.1)
mIAS mTOR inhibitor-associated stomatitis
a The mIAS Scale was speciﬁcally developed to measure mTOR inhibitor-associated stomatitis [13]
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mucositis. Mucositis pain was assessed by
patients as mild in two cases after the
second cycle, while four and six patients
after the second and third cycle had
moderate mucositis-associated pain, and
three and four patients had severe pain after
the second and third cycles, respectively.
Clinician-assessed grade 3 mucositis (visible
oral and/or pharyngeal ulcerations persisting
for at least 7 days) was observed in three
patients after the second cycle and in four
patients after the third cycle. Mucositis was
grade 1 or 2 in the other cases (Table 2).
Patients received everolimus administered
orally by continuous daily dosing.
A Kaplan–Meier survival analysis showed that
the estimated time to the development of
mucositis was a mean of 29.6 (median 18.0)
days (Fig. 1). A Cox regression analysis using
gender, age, performance status, tumor size,
node status and treatment line as covariates,
found that only tumor size significantly
influenced time to mucositis onset (Table 3):
time to development of mucositis was
significantly higher in patients with bigger
tumor size (T = 4) than in patients with the
Fig. 1 Kaplan-Meier estimates of time to the development of everolimus-related mucositis
Oncol Ther (2016) 4:275–286 281
smallest cancers. It must be noted here that, due
to the small sample size, this latter analysis
should be considered exploratory.
In one of the patients (50.0%) who had
mucositis at day 8 of the first cycle, mucositis
resolved during the second cycle of therapy
(Fig. 2). All the patients with mucositis at the
second cycle had the event resolve during the
third cycle of therapy. The Kaplan–Meier
survival analysis showed that the estimated
time to resolution of mucositis was a mean of
31.4 (median 30.0) days (Fig. 2). The only
patient who did not have resolution of
mucositis during the third cycle of therapy
experienced severe pain and grade 3 mucositis
at day 8. No variation of mucositis severity was
observed at the second cycle of therapy in this
patient, but at the third cycle mucositis pain
was decreased to moderate severity and the
degree of mucositis was grade 2.
Interruption of Therapy
Only one patient (5.3%) required suspension of
everolimus treatment on day 8 of therapy due
to everolimus-induced mucositis. After each of
the second and third cycles two patients
(10.5%) had to suspend everolimus treatment.
No everolimus dose reductions for mucositis
were necessary.
Pain Therapy by Cycle
Systemic pain therapy for cancer-related pain
was required by four patients (21.1%) during
the first and second cycles and by three patients
(15.8%) during the third cycle. Pain therapy for
everolimus-induced mucositis was required by
two patients (10.5%) during the first cycle, six
patients (31.6%) in the second cycle and eight
patients (42.1%) during the third cycle
(Table 4). In all cases, NSAIDs were the only
analgesics prescribed for mucositis-related pain.
DISCUSSION
All patients undergoing everolimus therapy in
our study were provided with the combination
of standardized suggestions for the prevention
of mucositis and the use of the galenical
preparation, as part of the support offered by
Table 3 Cox regression analysis for time to mucositis
Variables in the equation
b SE Wald df Sig Exp(b) 95% CI for Exp(b)
Lower Upper
Gender 0.541 0.937 0.333 1 0.564 1.718 0.274 10.790
Age 0.053 0.029 3.300 1 0.069 1.055 0.996 1.117
ECOG –0.690 0.628 1.208 1 0.272 0.502 0.147 1.716
Tumor size 1.396 0.563 6.137 1 0.013 4.037 1.338 12.180
Node status 0.416 0.482 0.745 1 0.388 1.516 0.589 3.900
Line 0.594 0.410 2.096 1 0.148 1.811 0.811 4.044
Time: time to mucositis onset
Status: mucositis y/n
Covariates: gender, age; performance status; tumor size (T); node status (N); treatment line
Only tumor size (bold) signiﬁcantly inﬂuenced time to mucositis onset
CI conﬁdence interval, df degrees of freedom, SE standard error of the mean, sig signiﬁcance, Exp exponential
282 Oncol Ther (2016) 4:275–286
our outpatient clinic dedicated to effectively
managing and monitoring the administration
of oral therapies. This allowed not only the
disease patterns of everolimus-related mucositis
to be identified and responded to more readily
but, most importantly, in almost all cases there
was no need to interrupt everolimus treatment.
When mucositis occurred, the use of a novel
preparation formulated with a corticosteroid
(dexamethasone) and rose honey enabled rapid
resolution of the mucositis with minimal need
for systemic analgesic use. No patient needed
opioids for mucositis pain. In those patients
who required analgesics for everolimus-related
mucositis, common NSAIDs (nimesulide,
ketorolac, aspirin) were all that were required
to control pain.
Fig. 2 Kaplan-Meier estimates of time to mucositis resolution









For cancer 4 (21.1) 4 (21.1) 3 (15.8)
NSAIDs 4 (21.1) 4 (21.1) 3 (15.8)
Opioids 1 (5.3) 1 (5.3) 1 (5.3)
For mucositis 2 (10.5) 6 (31.6) 8 (42.1)
NSAIDs 2 (10.5) 6 (31.6) 8 (42.1)
NSAIDs nonsteroidal anti-inﬂammatory drugs
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Aswith othermTOR inhibitors, oralmucositis
can be a significant dose-limiting adverse event
of everolimus therapy. For example, in three
recent trials of everolimus plus exemestane in
women with advanced breast cancer,
39.8–56.0% of patients experienced at least one
episode of everolimus-related mucositis, which
was grade 3/4 in approximately 8% of patients
[1, 14, 15]. This is similar to that reported in
patients with renal cell carcinoma [2]. Dose
reductions because of mucositis were necessary
in over 20% of patients, and everolimus
treatment interruptions for a median of
7–17 days were necessary in approximately
40–60% [1, 14, 15]. In contrast, no patient in
our studyhad amucositis-relateddose reduction,
and after the first, second, and third cycles of
therapy, only 5.3%, 10.5% and 10.5% of patients
required treatment interruptions.
Of interest, in an interimanalysis of theBRAWO
study, a large, German non-interventional study,
which will ultimately enroll 3000 patients with
advanced breast cancer receiving everolimus plus
exemestane, recommendations on stomatitis
prevention similar to those in our study were
given to 86.8% of patients. A total of 39.8% of
patientshadat leastonemucositis event,whichwas
grade2 in17.0%andgrade3 in3.4%. Inaddition to
dose reductionor treatment interruption, a rangeof
therapeutic interventions for mucositis were
utilized, alone or in combination, including
non-drug mouthwashes, cooling strategies such as
sucking ice, and systemic or topical drug
interventions (not further specified) [14].
The use of topical or systemic treatment
with corticosteroids has been shown to be
successful in resolving mucositis in the majority
of patients with mTOR inhibitor-related
mucositis [6, 7, 9, 10, 12, 16], and our
findings show that early intervention with a
dexamethasone-containing galenical preparation
is effective in managing mucositis. By integrating
appropriate instruction on good oral hygiene
designed to prevent mucositis, effective
monitoring for the development of mucositis,
and the provision of an effective treatment for use
at thefirst signsofmucositis into themanagement
plan of all patients undergoing treatment with
everolimus, treatmentadherencecanbe improved
to help ensure the best therapeutic outcome.
Furthermore, in some, if not all cases, a galenical
preparation such as that used in our institution
will be more cost-effective than proprietary
formulations.
Although the retrospective study design,
small patient numbers and absence of a
control group (due to the fact that all patients
at our institution who are receiving everolimus
are put on the program described to minimize
the impact of mucositis) can be considered a
limitation of our analysis, our standardized
approach to instructing and supporting
patients undergoing everolimus therapy is a
study strength, and the specially-prepared
galenical formulation significantly limited the
negative effects of mucositis.
CONCLUSIONS
The dose-limiting effects of everolimus-related
mucositis can be minimized by successfully
educating patients about the importance of
oral hygiene in combination with an effective
medicinal product that can be manufactured in
the hospital pharmacy or other galenical
laboratory and provided to the patient to be
used at the first signs of mucositis.
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